{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-129712","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.531418+00:00","generated_at":"2026-06-16T05:12:51.324283+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Acrivon provides pipeline and AP3 update, reports cash runway into Q4 2024","bullets":["Hosted virtual investor event on May 1, 2023 with updated corporate presentation.","Disclosed cash and marketable securities as of March 31, 2023 (amount not specified in filing).","Confirmed cash runway extends into at least Q4 2024.","Presentation highlights progress on AP3 precision proteomics platform and pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-129712","json":"https://secwatch.observer/filing/0001193125-23-129712.json","markdown":"https://secwatch.observer/filing/0001193125-23-129712.md","text":"https://secwatch.observer/filing/0001193125-23-129712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523129712/0001193125-23-129712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523129712/d283996d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:12:51.324283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}